Company Overview

Dyadic International, Inc. is a biotechnology company focused on developing and commercializing proprietary microbial platforms for the large-scale production of enzymes, proteins, and other biologics. The company operates primarily within the industrial biotechnology, biopharmaceutical, and life sciences industries. Dyadic’s core business centers on licensing and co-developing its C1 Expression System, a genetically optimized fungal platform designed to produce complex proteins efficiently, at high yield, and at lower cost compared to traditional systems.

The company generates revenue primarily through technology access agreements, research collaborations, upfront payments, milestone payments, and royalties tied to commercial products developed using its platform. Dyadic serves pharmaceutical and biotechnology companies, vaccine developers, and industrial enzyme producers. Its strategic advantage lies in the scalability, flexibility, and cost-efficiency of the C1 platform, particularly for biologics and vaccine antigens. Founded in 1979, Dyadic originally focused on industrial enzymes before transitioning toward biologics and pharmaceuticals following the divestiture of its industrial enzyme business in the mid-2010s, reshaping the company into a platform-based biotechnology licensor.

Business Operations

Dyadic’s operations are centered on a single reportable segment focused on biotechnology platform development and licensing. The company’s primary asset is the C1 Expression System, which is used to produce monoclonal antibodies, vaccines, and other therapeutic proteins. Revenue is generated through licensing agreements, collaborative development arrangements, and downstream royalties if partner-developed products reach commercialization. Dyadic maintains research and development capabilities but does not manufacture or market therapeutics directly.

The company operates in both domestic and international markets, with research activities primarily based in the United States and Netherlands. Dyadic has established partnerships with pharmaceutical and biotechnology organizations to evaluate and deploy its platform across multiple therapeutic areas. Its wholly owned subsidiary, Dyadic Nederland B.V., supports European research and development activities and intellectual property management.

Strategic Position & Investments

Dyadic’s strategy emphasizes expanding adoption of the C1 platform in human and animal health applications, particularly vaccines, infectious disease therapeutics, and monoclonal antibodies. Growth initiatives include entering additional licensing agreements, advancing internal proof-of-concept programs, and supporting partners through clinical development stages. The company has positioned itself to benefit from increased demand for scalable biologics manufacturing technologies.

Rather than pursuing large acquisitions, Dyadic focuses on selective investments in research collaborations and platform enhancements. It has engaged in multiple evaluation and development agreements with global pharmaceutical companies and public-sector organizations. The company is also involved in emerging areas such as next-generation vaccines and biologics targeting infectious diseases, where rapid, cost-effective protein production is a critical requirement.

Geographic Footprint

Dyadic is headquartered in Jupiter, Florida, with significant operations in Europe, primarily through its Dutch subsidiary. The company’s platform is licensed and evaluated by partners across North America, Europe, and other international markets, giving it a global operational and commercial reach despite its relatively small physical footprint.

Its geographic influence is driven less by direct facilities and more by intellectual property and collaborative arrangements that allow partners worldwide to deploy the C1 system in their own development and manufacturing environments. This asset-light model enables Dyadic to maintain international relevance without extensive capital-intensive infrastructure.

Leadership & Governance

Dyadic is led by an experienced executive team with backgrounds in biotechnology, pharmaceuticals, and corporate finance. The leadership emphasizes capital discipline, intellectual property protection, and long-term value creation through platform adoption rather than product commercialization.

Key executives include:

• Mark A. Emalfarb – Founder, President, and Chief Executive Officer
• Gerard Andrews – Chief Financial Officer
• Raul Vega – Chief Operating Officer
• Bruce A. Connell – Chief Business Officer
• Herman J. Smit – Chief Scientific Officer

The company’s governance framework is shaped by public company reporting standards and oversight by an independent board of directors, with strategic vision centered on transforming Dyadic into a leading enabling technology provider for biologics manufacturing.